The salmeterol/fluticasone propionate combination 50/100 μg bid is more effective than oral montelukast 10 mg od as a first line therapy in mild and moderate asthmatics

K. Rickard, P. M. Dorinsky, K. Knobil, P. Pepsin, M. L. M. Akveld (Research Triangle Park, United States Of America; Uxbridge, United Kingdom)

Source: Annual Congress 2001 - Leukotriene receptor antagonists in clinical practice
Session: Leukotriene receptor antagonists in clinical practice
Session type: Thematic Poster Session
Number: 1776
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
K. Rickard, P. M. Dorinsky, K. Knobil, P. Pepsin, M. L. M. Akveld (Research Triangle Park, United States Of America; Uxbridge, United Kingdom). The salmeterol/fluticasone propionate combination 50/100 μg bid is more effective than oral montelukast 10 mg od as a first line therapy in mild and moderate asthmatics. Eur Respir J 2001; 16: Suppl. 31, 1776

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The salmeterol/fluticasone propionate combination 50/100 μg b.i.d is effective as initial maintenance therapy in mild and moderate asthmatics
Source: Eur Respir J 2001; 18: Suppl. 33, 176s
Year: 2001

Salmeterol/fluticasone propionate combination 50/100 μg bid is more effective than fluticasone propionate 100 μg bid plus montelukast 10 mg once daily in reducing exacerbations
Source: Eur Respir J 2001; 18: Suppl. 33, 262s
Year: 2001

Comparison of once-daily ciclesonide 160 μg versus twice-daily fluticasone propionate 88 μg in children with moderate to severe asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 711s
Year: 2006

Once daily ciclesonide and twice daily fluticasone propionate are equally effective in the treatment of patients with asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 346s
Year: 2004

Superior efficacy of the salmeterol/fluticasone 50/100 mcg combination compared to fluticasone 200 mcg in children with uncontrolled asthma – the VIAPAED trial
Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma
Year: 2008


Once-daily, high-dose inhaled fluticasone propionate and salmeterol in patients having moderate asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 125s
Year: 2004

The effects of fluticasone propionate/salmeterole 50/100 μg bid in children with asthma versus beclometasone propionate 200 μg BD and fluticasone propionate 100 μg bid dry powder inhaletors
Source: Eur Respir J 2004; 24: Suppl. 48, 378s
Year: 2004

Ciclesonide 160 μg once daily compared with fluticasone propionate 250 μg twice daily in maintenance therapy of patients with stable asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 205s
Year: 2006

Effects of esomeprazole 40 mg twice-daily in adults with moderate to severe asthma who had been treated previously with inhaled steroids and long-acting β2-agonists
Source: Eur Respir J 2005; 26: Suppl. 49, 278s
Year: 2005

Lower systemic exposure to corticosteroid for fluticasone propionate/salmeterol (500/50mcg bd) compared to budesonide/formoterol (400/12mcg bd) administered via combination dry powder inhalers in subjects with COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 205s
Year: 2006

A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD
Source: Eur Respir J 2014; 43: 763-772
Year: 2014



Ciclesonide 80 μg or 160 μg once daily is comparable to fluticasone propionate 88 μg twice daily in the treatment of asthma patients
Source: Eur Respir J 2005; 26: Suppl. 49, 255s
Year: 2005

Effect of combination fluticasone propionate and salmeterol diskhaler in treatment of moderate to severe asthma: comparison of initial high dose, constant medium dose and placebo
Source: Eur Respir J 2001; 18: Suppl. 33, 123s
Year: 2001

Comparison of ciclesonide (MDI) once daily and fluticasone propionate (Diskus®) twice daily in the treatment of patients with moderate asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 666s
Year: 2006

Erdosteine 600mg, but not placebo and NAC 1200mg, restores airway response to inhaled salbutamol 200mcg in COPD
Source: Annual Congress 2007 - Mechanisms and new treatments of COPD
Year: 2007


Ciclesonide once daily (80 mg/d, 160 mg/d) versus fluticasone propionate twice daily (250 mg/d) in the treatment of patients with persistent asthma
Source: Annual Congress 2010 - Treatment options for asthma
Year: 2010

LATE-BREAKING ABSTRACT: ENERGITO: Efficacy and safety of once-daily combined tiotropium + olodaterol versus twice-daily combined fluticasone propionate + salmeterol
Source: International Congress 2015 – Emerging strategies for airway disease treatments
Year: 2015


Eight weeks of treatment with tiotropium plus fluticasone (t+f) produces an equally effective therapeutic response as salmeterol plus fluticasone (s+f) in subjects with moderate-to-severe asthma
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009


12 weeks comparing salmeterol/fluticasone proprionate (SFC, 50/100 microg b.d. diskus) versus fluticasone proprionate (FP, 250 microg b.i.diskus) as first-line regular asthma treatment
Source: Eur Respir J 2003; 22: Suppl. 45, 236s
Year: 2003

Salmeterol/fluticasone propionate combination (SFC) versus doubling dose of fluticasone propionate (FP) in children with asthma insufficiently controlled on moderate doses of inhaled corticosteroids
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010